Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

IDWeek 2013: Older People Respond Equally Well to Telaprevir Triple Therapy for Hepatitis C

Interferon-based therapy with telaprevir (Incivek or Incivo) produced a similar cure rate with no notable increase in side effects or treatment discontinuation for genotype 1 chronic hepatitis C patients over age 60, Japanese researchers reported at the second IDWeek conference held recently in San Francisco.

alt

Read more:

Telaprevir Triple Therapy Shows Activity Against HCV Genotype 4

The HCV protease inhibitor telaprevir (Incivek or Incivo) in combination with pegylated interferon and ribavirin reduced viral levels by more than 4 log in people with genotype 4 hepatitis C in a short Phase 2a study, researchers reported in the September 15, 2013 Journal of Infectious Diseases.

alt

Read more:

DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy

People previously treated with interferon-based therapy can achieve good results when retreated with boceprevir (Victrelis) triple therapy, according to final results from the PROVIDE study presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando. Prior relapsers had the best response, but even 41% of prior null responders achieved a cure.

alt

Read more:

EASL 2013: 12 Weeks of Telaprevir Triple Therapy Adequate for Some Hep C Patients

Nearly 90% of genotype 1 chronic hepatitis C patients with favorable response factors including the IL28B CC gene variant achieved a cure with just 12 weeks of telaprevir (Incicek or Incivo) plus pegylated interferon/ribavirin, rising to 97% for those treated for 24 weeks, researchers reported at the recent EASL International Liver Congress (EASL 2013) in Amsterdam.

alt

Read more:

DDW 2013: Drug Interactions May Compromise Response to Boceprevir and Telaprevir

Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C, according to study findings presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.

alt

Read more: